EUVIMEDEUVIMED entdecken
Crossref

Duration of antibiotic therapy for pediatric ventilator‐associated pneumonia

Dauer der Antibiotikatherapie bei pädiatrischer ventilatorassoziierter Pneumonie

Aki Miyashita iD, Hanako Funakoshi iD, Meiwa Shibata iD, Osamu Saito, Keiko Nakamura, Shigeko Miyokawa, Yuho Horikoshi iD

Pediatrics International · 2025-01 · 67 (1)

DOI: 10.1111/ped.70262 ↗

Auf einen Blick

Bei 90 Kindern mit ventilatorassoziierter Pneumonie lag die mediane Antibiotikadauer bei 6 Tagen. Unter einer 6- bis 7-tägigen Therapie traten keine VAP-bedingten Todesfälle auf.

Fragestellung

Wie lange dauerte die Antibiotikatherapie bei pädiatrischer ventilatorassoziierter Pneumonie und welche klinischen Ergebnisse wurden beobachtet?

Methode

Retrospektive Kohortenstudie in der PICU eines tertiären Kinderkrankenhauses; Kinder <18 Jahre mit VAP zwischen April 2016 und Juni 2023.

Ergebnisse

90 Patient:innen. Medianes Alter 19 Monate; 44 % Mädchen. Median 6 Tage Antibiotika (IQR 6–7). Mortalität an Tag 7: 1 %; an Tag 28: 6 %; Rezidivrate 10 %.

Schlussfolgerung der Autor:innen

Die meisten Patient:innen erhielten eine 6- bis 7-tägige Antibiotikatherapie ohne adverse Outcomes. Rezidivrate sowie ventilations- und PICU-freie Tage waren mindestens vergleichbar mit früheren Erwachsenenberichten.

Kernaussagen

  • Median 6 Tage Antibiotika bei pädiatrischer VAP
  • Keine VAP-bedingten Todesfälle berichtet
  • Rezidivrate 10 %; median 22 ventilationsfreie Tage an Tag 28

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Pediatrics International, online erschienen am 01.12.2025. Verfasst von Aki Miyashita und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Pneumonia, Ventilator-Associated, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although a seven‐day course of antibiotic therapy for ventilator‐associated pneumonia (VAP) is recommended for adult patients, the optimal duration in children remains unclear. Our study described the management of pediatric VAP by focusing on the treatment and clinical outcomes.

Methods

We performed a retrospective cohort study in the Pediatric Intensive Care Unit (PICU) of a tertiary children's hospital. Children under 18 diagnosed with VAP between April 2016 and June 2023 were included. VAP was defined by the Centers for Disease Control and Prevention of the United States criteria. Exclusion criteria included co‐infections or a lack of prior antibiotic therapy. Demographic and microbiological data were collected from medical records.

Results

Ninety patients were eligible for enrollment. The median age was 19 months (IQR: 10–69 months) and 44% were girls. The median pediatric index of mortality‐2 score was 4 (IQR: 1.3–8.6). Staphylococcus aureus was the most frequently isolated pathogen (28%), followed by Pseudomonas aeruginosa (22%). The median length of antibiotic therapy was six days (IQR: 6–7 days). Mortality on days 7 and 28 was 1% ( n = 1) and 6% ( n = 5), without VAP‐related deaths. The recurrence rate was 10% ( n = 9). The median ventilation‐free and PICU‐free days at day 28 were 22 and 17, respectively.

Conclusion

Most patients received a six to seven‐day course of antibiotic therapy without adverse outcomes. The recurrence rate and the ventilation‐free and PICU‐free days were equivalent to or better than those reported previously for adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumonia, Ventilator-AssociatedAnti-Bacterial AgentsHumansFemaleRetrospective StudiesMaleChild, PreschoolInfantChildIntensive Care Units, PediatricDuration of TherapyTreatment Outcome

Stichwörter der Autor:innen

antibioticsinfectionpediatricspneumoniaventilators

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
  • Department of Pediatric Emergency and Critical Care Medicine, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
  • Department of Nursing, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
  • Department of Nursing, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.

ORCID-Profile: Aki Miyashita, Hanako Funakoshi, Meiwa Shibata, Yuho Horikoshi

Zitieren

APA

Miyashita, A., Funakoshi, H., Shibata, M., Saito, O., Nakamura, K., Miyokawa, S., & Horikoshi, Y. (2025). Duration of antibiotic therapy for pediatric ventilator‐associated pneumonia. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70262

Vancouver

Miyashita A, Funakoshi H, Shibata M, Saito O, Nakamura K, Miyokawa S, et al. Duration of antibiotic therapy for pediatric ventilator‐associated pneumonia. Pediatrics International. 2025;67(1). doi:10.1111/ped.70262

BibTeX
@article{Miyashita2025,
  author = {Miyashita, Aki and Funakoshi, Hanako and Shibata, Meiwa and Saito, Osamu and Nakamura, Keiko and Miyokawa, Shigeko and Horikoshi, Yuho},
  title = {Duration of antibiotic therapy for pediatric ventilator‐associated pneumonia},
  journal = {Pediatrics International},
  year = {2025},
  volume = {67},
  number = {1},
  doi = {10.1111/ped.70262}
}
Kostenlos starten →